The expanding approvals for pharmaceuticals based on cannabis is good news for Ukraine where the growth of industrial hemp is already developed and expanding.
By Sharon Harris for Born2Invest, July 3, 2018 Following the news of Canada approving the legalization of marijuana, there has been another significant development for the plant in the United States. On June 26, the U.S. Food and Drug Administration (FDA) approved a drug derived from cannabis, a first for the agency. According to CNN, a drug named Epidiolex received recommendations for approval, by an advisory committee, last April. The FDA has now been directed, by an advisory committee, to make a choice within the week. The agency released a statement on Monday, with Commissioner Dr. Scott Gottlieb released a statement on Monday saying that the drug “is an important medical advance.” “Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery,” he added. GW Pharmaceuticals created Epidiolex, and the company described it as the “first pharmaceutical formulation of highly-purified, plant-based cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.” CBD is in the good graces of the FDA as the agency green-lit some cannabinoids in their artificial forms to be used in various applications such as a relief for cancer. […] https://born2invest.com/articles/fda-a ... s-cannabis-drug-epilepsy/
| 